Engflag

Gynophilus

Quick links to important sections

Gynophilus

Gynophilus_FR

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gynophilus

Property Description
Active Ingredient Lactobacillus casei rhamnosus (Lcr35 strain), Lactobacillus casei V
Form Vaginal capsule, Vaginal tablet (sustained-release)
Pharmacological Class Gynaecological probiotic / Vaginal eubiotic agent
Common Use Restoration of the vaginal flora (microbiota)
Origin Natural constituents (Live Biotherapeutic Product - LBP)

What Type of Product is Gynophilus?

Gynophilus is classified as a Live Biotherapeutic Product (LBP), placing it within the pharmacological class of gynaecological probiotics or vaginal eubiotic agents. It is delivered via the local vaginal route in forms such as immediate-release vaginal capsules and specialized sustained-release vaginal tablets (often marketed as Gynophilus LP). This product utilizes natural constituents—live cultures of beneficial bacteria—to restore the proper microbial environment.

Composition: What Are the Active Ingredients in Gynophilus?

The primary active ingredients in Gynophilus are specific, viable cultures of Lactobacillus casei rhamnosus (Lcr35 strain) and Lactobacillus casei V, which are delivered as a freeze-dried lyophilized powder. These strains are closely related to the Döderlein bacillus group, which is a characteristic component of a healthy vaginal ecosystem. The specific Lcr35 strain is utilized for its adhesive and colonizing properties within the vaginal environment. The formulation is designed for direct topical action, often including an inert lactose carrier that serves as a nutrient base to ensure the viability and successful establishment of the beneficial bacteria.

Gynophilus’s General Purpose and Role in Flora Balance

The general purpose of Gynophilus is to restore and maintain the microbial balance of the vagina by supporting the body’s natural biological defense mechanisms. This effect is achieved through the colonization by the protective Lactobacillus and their subsequent lactic acid production. The sustained presence of Lactobacillus helps maintain the vaginal pH in its protective acidic state, typically between 3.8 and 4.5. By stabilizing the environment, Gynophilus helps to alleviate common symptoms associated with flora imbalance, such as general vaginal discomfort, itching, and unusual odor.

Regulatory References

  1. EFSA on Qualified Presumption of Safety (QPS)
  2. NIH MedlinePlus on Döderlein Bacilli

What side effects are possible with Gynophilus?

Possible Side Effects and Safety Information

The safety profile of Gynophilus, a Live Biotherapeutic Product (LBP) containing Lactobacillus casei rhamnosus, is characterized by adverse reactions that are generally localized and transient, as documented in official regulatory sources and clinical data. No severe adverse events directly attributed to the treatment have been reported in clinical trials.

Officially Documented Adverse Reactions

Adverse effects are principally confined to the application site, aligning with the Reproductive system and breast disorders System-Organ-Class. The most common or expected reactions are localized:

  • Transient Local Discomfort: This category includes temporary vaginal tingling, burning sensation, or itching (pruritus), which may be more frequently observed at the start of treatment.
  • Worsening of Pre-existing Symptoms: A temporary increase in local symptoms, such as discharge or irritation, can occur during the initial phase.

Serious reactions are rare. The principal serious risk defined by regulatory documents is Hypersensitivity (allergic reaction) to any component, which serves as a formal contraindication.

Safety Restrictions and Limitations

Official labeling contains specific constraints concerning use in certain populations and in conjunction with other products, defining the boundaries of regulatory safety:

  • Contraindication for Hypersensitivity: The product is strictly restricted for use in individuals with a known allergy to the active substance or excipients.
  • Population Restrictions: Use is generally contraindicated for children. Consultative use is advised regarding pregnancy and breastfeeding, due to limited data in these specific groups.
  • Co-administration Restrictions: Use is restricted with spermicides or latex contraceptive membranes (e.g., condoms), as regulatory documents indicate a potential to reduce contraceptive integrity or effectiveness.

This information structures the official safety profile around mild, local, temporary reactions and defined contraindications, with no reported severe adverse events in clinical studies.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Official regulatory documentation for Gynophilus, a Live Biotherapeutic Product, confirms no specific cases of overdose have been reported in typical use by healthy individuals. Due to the product's local administration and high safety profile, acute systemic toxicity manifestations are not cataloged in official labeling.

Documented Risk in Specific Populations: While acute overdose signs are absent for the general user, government health authorities recognize a risk of systemic infection (bacteremia or septicemia) associated with the Lactobacillus class. This severe outcome is specifically confined to high-vulnerability patient groups, including those who are severely ill or immunocompromised, or patients with central venous catheters.

Emergency-Response Statements

Immediate medical attention must be sought in the event of suspected ingestion or misuse that far exceeds the recommended local dose. When seeking help, patients should be prepared to provide the attending physician with the medicine packaging or label. Treatment in the case of suspected overdose is officially limited to symptomatic and supportive measures, as no specific antidote is known or documented.

Overdose Classifications

The regulatory classification of the overdose scenario reflects a low acute systemic toxicity for typical use, with the primary constraint being the required hospital monitoring for at-risk individuals who exhibit signs of potential systemic illness.

Therapeutic Uses of Gynophilus

What Gynophilus treats: Main Uses and Benefits

The primary therapeutic role of Gynophilus is defined by its ability to support the stability of the vaginal ecosystem, providing supportive symptomatic relief and assistance against the recurrence of imbalance.

Gynophilus is commonly used to help with conditions characterized by temporary physiological imbalance, specifically conditions presenting with symptoms related to systemic imbalance, or dysbiosis. Its main benefit is to support the environment and assist with maintaining functional stability, particularly after disruptions such as antibiotic treatment.

The product is relevant for easing symptom clusters that may become intense or disruptive, helping to address pronounced symptoms of vaginal itching (pruritus), general irritation, and managing manifestations linked to unusual odor and abnormal discharge. It is considered relevant for managing conditions that involve recurrent or episodic manifestations.

“It provides supportive relief when symptoms interfere with routine activities.”

This product is applied across domains where additional symptomatic support is needed, assisting with flora recovery post-treatment and is relevant for managing situations involving chronic recurrence. This approach supports patients during episodes of heightened discomfort and may help reduce the likelihood of symptoms that become more disruptive during flare-ups.

Quick Fact: Relief for Vaginal Sensory Discomfort

Regulatory References

  1. NHS Scotland clinical guidelines on vaginal discharge

Eligibility and Restrictions for Use

Who can and cannot use Gynophilus? — Official Regulatory Information

This section outlines the documented population eligibility rules and contraindications for Gynophilus, based strictly on official regulatory labeling.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adult women are the standard target population for whom the product is indicated for use.
Populations for whom use is not recommended Use is not recommended for children (pre-pubescent girls) and is not indicated for this population.
Populations for whom use is contraindicated Patients with a known hypersensitivity or allergy to the active ingredients (Lactobacillus casei rhamnosus, Lactobacillus casei V) or any excipient.
Age-related eligibility rules Primarily intended for use in the adult female population. Not to be used for children.
Condition-specific eligibility rules Contraindicated in females presenting with vaginal or vulval lesions or open wounds. Systemic conditions, such as severe hepatic or renal impairment, are typically not listed as formal exclusions due to the product’s local action.
Pregnancy and lactation eligibility status Use during breastfeeding is generally considered acceptable. Use during pregnancy is possible but some regulatory documents state it is not indicated.

--раите-

Eligibility Classifications (High-Level)

Classification Official Regulatory Wording
Eligibility severity classification Contraindicated (for allergy/lesions); Not Recommended (for children); Acceptable/Possible (for adult/lactation).
Eligibility-context constraints Constraints are primarily allergic (hypersensitivity) and anatomical (age and local tissue integrity).

Connection to the overall eligibility profile

Regulatory documents define eligibility by establishing absolute exclusions based on local allergic reactions and tissue integrity, while restricting use to the adult female population. The local route of administration is the primary basis for the minimal restrictions concerning severe systemic conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Gynophilus, a local-acting Live Biotherapeutic Product (LBP), is defined by necessary restrictions to prevent functional antagonism at the site of application. These interactions are documented in regulatory sources and primarily involve functional conflicts rather than systemic pharmacokinetic changes.

Documented Pharmacodynamic and Functional Conflicts

Interacting Substance Category Official Regulatory Restriction Rationale as Stated in Labeling
Vaginal Anti-infective Medicinal Products Simultaneous co-administration is strictly prohibited. Functional Antagonism: The anti-infective agent will destroy the active, beneficial Lactobacillus strains.
Spermicides (Chemical Contraceptives) Co-administration is restricted. Risk of compromising the efficacy and primary function of the contraceptive product.
Latex Contraceptive Barriers Advisement against simultaneous use. Potential for certain formulation excipients to affect the physical integrity of the latex material.

Administration Timing and Class Cautions

Administration requires mandatory temporal separation from any course of vaginal anti-infective treatment to ensure the survival and successful colonization of the live bacterial cultures. The product must only be introduced after the anti-infective treatment has been concluded.

Furthermore, regulatory documentation for the LBP class includes a general population-specific caution noting the theoretical risk associated with use in severely immunosuppressed individuals. No systemic pharmacokinetic interactions, such as those involving CYP enzymes or drug transporters, are documented for this locally acting product.

Mechanism of Action

Mechanistic Action of Lactobacillus Colonization

Gynophilus's mechanism of action begins with the adhesion and colonization of the vaginal epithelium by the active Lactobacillus strain. This organism initiates a metabolic cascade by converting local carbohydrates into lactic acid. The resulting reduction of the vaginal pH to its acidic range (approximately 3.5 –4.5) establishes a powerful selective pressure against pH-sensitive, non-commensal flora.

This physiochemical change is complemented by a process of competitive inhibition for epithelial binding sites. Further mechanistic action involves the production of specific antimicrobial metabolites such as hydrogen peroxide ( H2 O2) and bacteriocins, which chemically interfere with the proliferation of other organisms. Beyond microbial control, the colonizing Lactobacillus contributes to altering innate immunity through localized cytokine signaling regulation, which affects the physical integrity of the mucosal barrier and influences physiological responses within the vaginal tissue.

Dosage and Administration Information

The administration of Gynophilus is strictly local, utilizing the vaginal route for delivery of its Lactobacillus cultures. The product is available in two main official dosage forms: an immediate-release vaginal capsule and a sustained-release vaginal tablet (often marketed as Gynophilus LP). Administration is exclusively for adults only.

The regimen is defined by the formulation used. For the immediate-release capsule, the standard initial course involves one capsule administered twice daily for seven continuous days. This is typically followed by a maintenance course of one capsule once daily for a subsequent 14-day duration, which can be repeated as necessary.

Conversely, the sustained-release tablet follows an intermittent schedule where one tablet is administered every four days, designed for prolonged local action. Before administration, the capsule or tablet must be briefly moistened with a little water to facilitate deep insertion and initiate product dissolution. Administration is generally recommended to occur in the evening, at bedtime, to maximize retention. A specific consideration is to avoid concurrent use with spermicidal products during the course of treatment. These different dosing patterns characterize the local administration of the live biotherapeutic product.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gynophilus

Evidence for Restoration of Vaginal Flora After Antibiotic Treatment

Research involves Randomized Controlled Trials (RCTs) examining adult women following antibiotic treatment for bacterial vaginosis (BV). Researchers measured vaginal flora restoration using the Nugent score to assess the return to a healthy composition. Studies report how Nugent scores were measured after application of the Lactobacillus strain compared to control groups. Long-term research on the prevention of BV recurrence remains an area of uncertainty, as findings across the broader evidence base were mixed.

Research on Non-Specific Imbalance & Special Populations

Studies have also explored non-specific vaginal flora imbalance using Pilot Clinical Trials. These focused on biological outcomes like successful colonization of the Lactobacillus strain rather than functional symptom resolution. Evidence for the prevention of recurrent yeast infections (VVC) includes preclinical laboratory studies where changes were observed in Candida growth, but dedicated clinical data remains developing. Similarly, research on pregnant women with an intermediate microbiota utilized small, specialized studies to monitor Nugent score change, but data for this particular group remain insufficient for strong conclusions.

Key Evidence Gaps and Areas of Uncertainty

The overall evidence base has limitations that affect certainty. Sample sizes were modest in many trials, and follow-up durations were limited, meaning long-term effects are not well characterized. Comparative evidence is lacking, and results for certain groups remain insufficient to draw generalizable conclusions.

Key Studies & References

  1. Probiotics for the prevention of recurrent bacterial vaginosis: a systematic review and meta-analysis

How should Gynophilus be stored and disposed of?

How to Store and Dispose of Gynophilus

Storage of Gynophilus vaginal capsules must adhere strictly to regulatory requirements to maintain the viability of the Lactobacillus active ingredients.

Official Storage Conditions

Requirement Specific Regulatory Statement
Temperature Store at a temperature not exceeding 25°C.
Protection The product must be kept dry and protected from moisture.
Child Safety Keep the medicine out of the sight and reach of children.
Stability Do not use past the expiration date printed on the package.

Disposal Instructions

Official disposal protocols prohibit discarding Gynophilus via wastewater or household waste. Unused or expired medicine should be returned to a pharmacist for proper handling and environmental protection, as required by regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Gynophilus found in:

A-Z Index: